INDP

Indaptus Therapeutics, Inc. [INDP] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INDP Stock Summary

Top 10 Correlated ETFs

INDP

Top 10 Correlated Stocks

INDP

In the News

INDP Financial details

Company Rating
-
Market Cap
23.65M
Income
-15.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-1.09
Forward P/E
-
PEG
-1.13
P/S
-
P/B
1.03
P/C
-
P/FCF
-1.21
Quick Ratio
6.75
Current Ratio
7.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.82
EPS next Y
-
EPS next Q
-
EPS this Y
10.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
2.13%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-81%
ROE
-72%
ROC
-1.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.56-4.08
52W High
-60.5%
52W Low
+58%
RSI
38
Rel Volume
0.46
Avg Volume
86.05K
Volume
39.92K
Perf Week
-10.23%
Perf Month
-21.78%
Perf Quarter
-59.69%
Perf Half Y
-47.16%
-
-
-
-
Beta
1.225
-
-
Volatility
0.08%, 0.13%
Prev Close
-7.06%
Price
1.58
Change
-14.13%

Something similar

Top by Market Cap
JPM
BRH.DE
BRK-A
CMC.DE
NVDA
Top Correlated ETFs
ZWC.TO
UC87.L
PPI
FCCD.TO
TQCD.TO
Top Correlated Stocks
IMPUY
CATE.ST
CSX
AMUN.PA
FVI.TO
Similar Market Cap
CMET.L
TGGR.TO
CNRD
SQNS
BKI.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 86.05K
  • Market Capitalization 23.65M
  • Employee 7
  • CEO Mr. Jeffrey A. Meckler
  • Headquarters New York,NY,US
  • IPO Date 2015-08-04
  • Website https://indaptusrx.com

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.